Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Düring, J, Annborn, M, Cronberg, T, Dankiewicz, J, Devaux, Y, Hassager, C, Horn, J, Kjaergaard, J, Kuiper, M, Nikoukhah, HR, Stammet, P, Undén, J, Wanscher, MJ, Wise, M, Friberg, H & Nielsen, N 2020, 'Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial', Critical Care, vol. 24, no. 1, pp. 185. https://doi.org/10.1186/s13054-020-02904-8

APA

Düring, J., Annborn, M., Cronberg, T., Dankiewicz, J., Devaux, Y., Hassager, C., Horn, J., Kjaergaard, J., Kuiper, M., Nikoukhah, H. R., Stammet, P., Undén, J., Wanscher, M. J., Wise, M., Friberg, H., & Nielsen, N. (2020). Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial. Critical Care, 24(1), 185. https://doi.org/10.1186/s13054-020-02904-8

CBE

Düring J, Annborn M, Cronberg T, Dankiewicz J, Devaux Y, Hassager C, Horn J, Kjaergaard J, Kuiper M, Nikoukhah HR, Stammet P, Undén J, Wanscher MJ, Wise M, Friberg H, Nielsen N. 2020. Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial. Critical Care. 24(1):185. https://doi.org/10.1186/s13054-020-02904-8

MLA

Vancouver

Author

Düring, Joachim ; Annborn, Martin ; Cronberg, Tobias ; Dankiewicz, Josef ; Devaux, Yvan ; Hassager, Christian ; Horn, Janneke ; Kjaergaard, Jesper ; Kuiper, Michael ; Nikoukhah, Homa Rafi ; Stammet, Pascal ; Undén, Johan ; Wanscher, Michael Jaeger ; Wise, Matt ; Friberg, Hans ; Nielsen, Niklas. / Copeptin as a marker of outcome after cardiac arrest : a sub-study of the TTM trial. In: Critical Care. 2020 ; Vol. 24, No. 1. pp. 185.

Bibtex

@article{059c7f210b584d168bf7c2057e4699cf,
title = "Copeptin as a marker of outcome after cardiac arrest: a sub-study of the TTM trial",
abstract = "BACKGROUND: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.METHODS: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score.RESULTS: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001.CONCLUSION: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure.TRIAL REGISTRATION: Clinical Trials, NCT01020916. Registered November 26, 2009.",
keywords = "Aged, Biomarkers/analysis, Female, Glycopeptides/analysis, Hospital Mortality, Humans, Male, Middle Aged, Odds Ratio, Organ Dysfunction Scores, Out-of-Hospital Cardiac Arrest/blood, Proportional Hazards Models, Statistics, Nonparametric",
author = "Joachim D{\"u}ring and Martin Annborn and Tobias Cronberg and Josef Dankiewicz and Yvan Devaux and Christian Hassager and Janneke Horn and Jesper Kjaergaard and Michael Kuiper and Nikoukhah, {Homa Rafi} and Pascal Stammet and Johan Und{\'e}n and Wanscher, {Michael Jaeger} and Matt Wise and Hans Friberg and Niklas Nielsen",
year = "2020",
month = apr,
day = "28",
doi = "10.1186/s13054-020-02904-8",
language = "English",
volume = "24",
pages = "185",
journal = "Critical Care",
issn = "1466-609X",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Copeptin as a marker of outcome after cardiac arrest

T2 - a sub-study of the TTM trial

AU - Düring, Joachim

AU - Annborn, Martin

AU - Cronberg, Tobias

AU - Dankiewicz, Josef

AU - Devaux, Yvan

AU - Hassager, Christian

AU - Horn, Janneke

AU - Kjaergaard, Jesper

AU - Kuiper, Michael

AU - Nikoukhah, Homa Rafi

AU - Stammet, Pascal

AU - Undén, Johan

AU - Wanscher, Michael Jaeger

AU - Wise, Matt

AU - Friberg, Hans

AU - Nielsen, Niklas

PY - 2020/4/28

Y1 - 2020/4/28

N2 - BACKGROUND: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.METHODS: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score.RESULTS: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001.CONCLUSION: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure.TRIAL REGISTRATION: Clinical Trials, NCT01020916. Registered November 26, 2009.

AB - BACKGROUND: Arginine vasopressin has complex actions in critically ill patients, involving vasoregulatory status, plasma volume, and cortisol levels. Copeptin, a surrogate marker for arginine vasopressin, has shown promising prognostic features in small observational studies and is used clinically for early rule out of acute coronary syndrome. The objective of this study was to explore the association between early measurements of copeptin, circulatory status, and short-term survival after out-of-hospital cardiac arrest.METHODS: Serial blood samples were collected at 24, 48, and 72 h as part of the target temperature management at 33 °C versus 36 °C after cardiac arrest trial, an international multicenter randomized trial where unconscious survivors after out-of-hospital cardiac arrest were allocated to an intervention of 33 or 36 °C for 24 h. Primary outcome was 30-day survival with secondary endpoints circulatory cause of death and cardiovascular deterioration composite; in addition, we examined the correlation with extended the cardiovascular sequential organ failure assessment (eCvSOFA) score.RESULTS: Six hundred ninety patients were included in the analyses, of whom 203 (30.3%) developed cardiovascular deterioration within 24 h, and 273 (39.6%) died within 30 days. Copeptin measured at 24 h was found to be independently associated with 30-day survival, hazard ratio 1.17 [1.06-1.28], p = 0.001; circulatory cause of death, odds ratio 1.03 [1.01-1.04], p = 0.001; and cardiovascular deterioration composite, odds ratio of 1.05 [1.02-1.08], p < 0.001. Copeptin at 24 h was correlated with eCvSOFA score with rho 0.19 [0.12-0.27], p < 0.001.CONCLUSION: Copeptin is an independent marker of severity of the post cardiac arrest syndrome, partially related to circulatory failure.TRIAL REGISTRATION: Clinical Trials, NCT01020916. Registered November 26, 2009.

KW - Aged

KW - Biomarkers/analysis

KW - Female

KW - Glycopeptides/analysis

KW - Hospital Mortality

KW - Humans

KW - Male

KW - Middle Aged

KW - Odds Ratio

KW - Organ Dysfunction Scores

KW - Out-of-Hospital Cardiac Arrest/blood

KW - Proportional Hazards Models

KW - Statistics, Nonparametric

U2 - 10.1186/s13054-020-02904-8

DO - 10.1186/s13054-020-02904-8

M3 - Journal article

C2 - 32345356

VL - 24

SP - 185

JO - Critical Care

JF - Critical Care

SN - 1466-609X

IS - 1

ER -

ID: 61746581